Analyst Price Target Update on PTC Therapeutics (NASDAQ:PTCT)

PTC Therapeutics (NASDAQ:PTCT): According to 6 Analysts, The short term target price has been estimated at $ 20.The target price could deviate by a maximum of $15.17 from the forecast price. In the near term, the target price could hit a high of $40 and a low of $ 8.

Many analysts have stated their opinion on the company shares. Brokerage firm Barclays maintains its rating on PTC Therapeutics (NASDAQ:PTCT). As per the latest information, the brokerage house lowers the price target to $40 per share from a prior target of $100. The shares have been rated Overweight. The rating by the firm was issued on March 1, 2016. Company shares have received an average consensus rating of Hold for the current week

On the companys insider trading activities, Rothera Mark, officer (Chief Commercial Officer) of Ptc Therapeutics, Inc., had purchased 2,000 shares on March 3, 2016. The total value of the transaction was $12,460. The information was disclosed with the SEC in a Form 4 Filing. The information is based on open market trades at the market prices.Option exercises are not covered.

PTC Therapeutics (NASDAQ:PTCT) stock ended Monday session in the red zone in a volatile trading. The stock closed down 0.38 points or 5.25% at $6.86 with 1,041,370 shares getting traded. Post opening the session at $7.16, the shares hit an intraday low of $6.84 and an intraday high of $7.42 and the price was in this range throughout the day. The company has a market cap of $235 million and the number of outstanding shares have been calculated to be 34,265,019 shares. The 52-week high of PTC Therapeutics (NASDAQ:PTCT) is $62.15 and the 52-week low is $5.27.

PTC Therapeutics, Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of orally administered, small molecule therapeutics that target post-transcriptional control processes. The Companys internally discovered pipeline addresses multiple therapeutic areas, including rare disorders, oncology and infectious diseases. The Companys lead product, Translarna (ataluren), is used for the treatment of genetic disorders due to a nonsense mutation in ambulatory patients aged five years and older. Ataluren is in clinical development for the treatment of Duchenne muscular dystrophy caused by a nonsense mutation (nmDMD) and cystic fibrosis caused by a nonsense mutation (nmCF).

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.